Celtek has developed a highly effective, patent-protected peptide agent (CB5005) that shows specific activity
in promoting significant levels of apoptosis of androgen-independent prostate cancer cells, either alone or in combination
with conventional chemotherapeutic drugs, such as cisplatin or etoposide.
CB5005, by virtue of its mechanism of
action, also has other therapeutic uses. Celtek is currently investigating the various therapeutic uses for CB5005 and is
actively developing it as a therapeutic agent for the treatment of cancer and other human diseases. CB5005’s first target
is androgen-independent prostate cancer, prostate cancer being the second leading cause of cancer-related deaths in the United
The company has successfully obtained funding for its research and development activities from the National
Institutes of Health. Celtek welcomes capital investment and joint development partnerships to obtain FDA approval of CB5005
and market the product for its many uses, starting with prostate cancer therapy.
In addition to CB5005, Celtek
team is also working on R&D of other cell-permeable peptide-based preclinical drug compounds, which may be therapeutically
effective for a variety of human diseases.